New research further confirms value of interrogating epigenomic
signals with Guardant Infinity™ platform to identify novel
biomarker targets and predict treatment resistance
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, announced today that the company and its research
collaborators will present data from 17 studies that highlight the
contribution of Guardant blood tests and real-world data to
advances in precision oncology and cancer screening at the 2023
American Society for Clinical Oncology (ASCO) Annual Meeting, June
2-6 in Chicago.
Data being presented from multiple studies demonstrate the
utility of Guardant Health’s portfolio of cancer tests to help
healthcare professionals optimize care for patients at all stages
of the disease—from detecting early-stage cancers to identifying
the presence of residual disease and delivering insights that
inform treatment to improve outcomes.
“We look forward to sharing new data at ASCO that demonstrate
scientific and clinical advances across the entire continuum of
cancer care,” said Helmy Eltoukhy, Guardant Health chairman and
co-CEO. “In particular, research demonstrating the tremendous
potential of epigenomic analysis through our new Guardant Infinity
platform shows how gaining deeper insights into the tumor
microenvironment can help us identify new potential biomarker
targets for therapy and predictive markers for treatment
resistance.”
Featured presentations include:
- Guardant Health will present a session highlighting the
performance of the Guardant Infinity platform in the detection of
homologous recombination deficiency (HRD) status in patients with
breast cancer. With HRD prediction, the platform provides a
comprehensive, minimally invasive solution for PARPi and DNA damage
treatment selection and longitudinal monitoring, and an exploratory
platform for investigating epigenetic signals that may underpin
resistance. (Abstract 556, Sunday, June 4, 8-11am, Hall A)
- Guardant Health collaborators will present a session on the
ESR1 mutational landscape and the impact of co-existing resistance
variants on clinical outcomes in patients with metastatic breast
cancer. The study demonstrates that plasma-based genotyping can
detect ESR1 mutations that qualify patients to receive FDA-approved
SERD therapy, including repeat testing over time even when an ESR1
mutation was not present in a past sample. The study also explores
additional co-mutations ascertained through broad genomic liquid
profiling and their impact on patient survival. (Abstract 1074,
Sunday, June 4, 8-11am, Hall A)
- Guardant Health collaborators will present results from
HERALD/EPOC1806, a multicenter, investigator-initiated phase 2
trial of T-DXd for patients with HER2 (ERBB2)-amplified advanced
solid tumors identified in cfDNA by Guardant360 (G360) as a part of
the Nationwide Cancer Genome Screening Project (GOZILA study) in
Japan. Results indicate that T-DXd achieved a high objective
response rate and durable response with a manageable safety profile
in patients with advanced solid tumors and HER2 amplification
detected in cfDNA. (Abstract 3014, Saturday, June 3, 1:15–2:45pm,
Grand Ballroom S100bc)
Complete list of Guardant Health and collaborator
presentations at ASCO
Abstract
Poster
Title (Hall A unless
otherwise noted)
Product
Saturday, June 3 | 8:00 am – 11:00 am
3030
228
Changes in ctDNA levels as an early
indicator of outcomes in advanced NSCLC treated with TKI: Initial
findings from a retrospective aggregate analysis of 8 clinical
trials
Guardant360®
3053
251
cfDNA NGS detection of fusions acquired as
mechanisms of resistance in the post-EGFR setting across multiple
solid tumors
Guardant360
3102
300
Efficacy and safety of futibatinib for
refractory advanced solid malignancies with FGFR alterations
identified in circulating tumor DNA: TiFFANY, A GOZILA-affiliated
Trial
Guardant360
2561
403
Clinical outcomes of immune checkpoint
inhibitor treatment in patients with classic cold tumors identified
to have a high tumor mutational burden via ctDNA
Guardant360
3049
247
ctDNA-based genomic landscape analysis to
evaluate molecular brake and gatekeeper mutations in FGFR2
alterations
GuardantINFORM™
Saturday, June 3 | 1:15 pm – 4:15 pm
3014
212
Tissue-agnostic efficacy of trastuzumab
deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification
identified by plasma cell-free DNA (cfDNA) testing: Results from a
phase 2 basket trial (HERALD/EPOC1806) (Note: Location is Grand
Ballroom S100bc)
Guardant360
TPS6654
145b
Understanding patient acceptance and
compliance of a blood-based colorectal cancer screening test
Shield™
Sunday, June 4 | 8:00 am – 11:00 am
556
386
Detection of homologous recombination
deficiency (HRD) using a novel genomic and epigenomic liquid biopsy
assay in patients with breast cancer
Guardant Infinity
9133
121
Investigating racial inequities of
circulating tumor DNA (ctDNA) use in patients with non-small cell
lung cancer: A real world analysis
Guardant360
1074
295
ESR1 mutational landscape and impact of
co-existing resistance variants on clinical outcomes in patients
with metastatic breast cancer
Guardant360
1081
302
Real-world outcomes of patients with
advanced breast cancer with and without resistance alterations
detected in cell-free circulating tumor DNA prior to CDK4/6
inhibitor plus endocrine therapy treatment
GuardantINFORM
9029
17
Impact of EML4-ALK fusion variant and
co-occurring TP53 mutation on treatment duration of first-line
next-generation ALK TKIs in ALK fusion+ NSCLC
GuardantINFORM
Monday, June 5 | 8:00 am – 11:00 am
3540
240
Does serial circulating tumor DNA (ctDNA)
monitoring identify additional acquired actionable alterations in
metastatic colorectal cancer (mCRC)?
Guardant360
TPS3625
324b
Phase II/III study of circulating tumor
DNA as a predictive biomarker in adjuvant chemotherapy in patients
with stage II colon cancer: NRG-GI005 (COBRA)
Guardant Reveal
3567
267
Reversion of RAS mutations in metastatic
colorectal cancer in the CCTG CO.26 clinical trial
GuardantOMNI™
TPS3626
325a
The Ohio State University Guardant Shield
Colorectal Cancer Screening Project
Shield
Monday, June 5 | 1:15 pm – 4:15 pm
TPS1610
203a
Screening for high frequency malignant
disease (SHIELD)
Shield (Next Generation)
The full abstracts for Guardant Health and a list of all
abstracts being presented at the meeting can be found at the ASCO
website here.
For more information and updates from the meeting, follow
Guardant Health on LinkedIn and Twitter or visit ASCO booth
#19119.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
tests, vast data sets and advanced analytics. The Guardant Health
oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched Guardant360®, Guardant360® CDx,
Guardant360 TissueNext™, Guardant360 Response™, and
GuardantINFINITY™ tests for advanced-stage cancer patients, and
Guardant Reveal™ for early-stage cancer patients. The Guardant
Health screening portfolio, including the commercially launched
Shield™ test, aims to address the needs of individuals eligible for
cancer screening. For more information, visit guardanthealth.com
and follow the company on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding the potential utilities, values, benefits and advantages
of Guardant Health’s liquid biopsy tests or assays, which involve
risks and uncertainties that could cause the actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect Guardant Health’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operation” and elsewhere in its Annual
Report on Form 10-K for the year ended December 31, 2022, and in
its other reports filed with or furnished to the Securities and
Exchange Commission thereafter. The forward-looking statements in
this press release are based on information available to Guardant
Health as of the date hereof, and Guardant Health disclaims any
obligation to update any forward-looking statements provided to
reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is based,
except as required by law. These forward-looking statements should
not be relied upon as representing Guardant Health’s views as of
any date subsequent to the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230531005345/en/
Investor Contact: Alex Kleban
investors@guardanthealth.com +1 657-254-5417
Media Contact: Michael Weist press@guardanthealth.com +1
317-371-0035
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024